22:52 , Jan 15, 2019 |  BC Week In Review  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
23:49 , Jan 14, 2019 |  BC Extra  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
18:17 , Jan 11, 2019 |  BC Week In Review  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
22:35 , Jan 9, 2019 |  BC Innovations  |  Translation in Brief

T cells: Life after exhaustion?

Weizmann Institute of Science and Netherlands Cancer Institute (NKI) scientists have shown dysfunctional T cells are not as "exhausted" as previously thought, but display proliferative activity and tumor recognition. In a Cell paper published on...
00:11 , Jan 8, 2019 |  BC Extra  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
19:25 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Response rate falls for Idera's TLR9 agonist plus Yervoy combo in melanoma

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) reported updated data showing that tilsotolimod (IMO-2125) plus Yervoy ipilimumab led to a lower overall response rate (ORR) in metastatic melanoma patients than what the company reported at this year's American...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
22:38 , Dec 14, 2018 |  BC Extra  |  Clinical News

Idera down on melanoma response data

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) lost $2.62 (40%) to $3.98 on Friday after reporting updated data showing that tilsotolimod (IMO-2125) plus Yervoy ipilimumab led to a lower overall response rate (ORR) in metastatic melanoma patients than...
20:58 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Imfinzi-tremelimumab combo fails Phase III for head and neck cancer

In yet another setback for tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in combination with PD-L1 inhibitor Imfinzi durvalumab missed the primary endpoint of improving overall survival (OS) compared with standard of care...